According to a report from Hemptoday on July 12, the Italian government has ignored a ruling from a regional administrative court and violated EU law by placing CBD on the country's list of narcotic drugs.
The Italian Ministry of Health stated that this regulation complies with Italian Presidential Decree 309/1990, which forms the cornerstone of Italy's drug legislation. However, this contradicts a ruling from a regional court last year, which was based on legally binding judgments within the European Union.
This is the latest move by the Italian government against CBD. In October 2020, the Ministry of Health classified CBD as a narcotic drug for the first time and banned it from the market, but soon after revoked the order.
In another attempt in early 2022, the national-regional conference updated the language in the 2018 regulation, officially categorizing marijuana as a medicinal plant.
In that scenario, four major cannabis associations filed a lawsuit and the Lazio Regional Administrative Court overturned the regulation a year later, ruling that it violated European law. The European Commission announced in 2020 that CBD is not a narcotic drug and can be legally traded between member states. This decision was based on a landmark ruling by the European Court of Justice the same year.
The Italian Farmers' Association, Cia-Agricoltori Italiani, criticized the government in a statement for not consulting producers before listing CBD as a dangerous drug, stating that this move "has insulted farmers who have invested money and work in the industrial hemp supply chain in recent years".
The farmer's organization stated that
This is not only a controversial measure from legal, health, and scientific perspectives, but also an intervention that could potentially make the already heavily strained supply chain even more complicated.
According to CIA-Agricoltori Italiani, these prejudices are further reflected in a current amendment in the Italian parliament, which aims to ban CBD and all other products derived from hemp flowers.
The group's chairman, Cristiano Fini, stated that
We are facing potential ideological interference that could paralyze a high-value-added supply chain that attracts young people. This supply chain has huge production potential in cosmetics, herbs, green construction, floriculture, and textiles, with an annual turnover of 500 million euros and providing over 10,000 jobs.
Currently circulating in parliament is a proposed amendment that would completely ban cannabis flowers, affecting various aspects of production and trade. The leading cannabis industry organization, Federcanapa, has expressed that the provisions would effectively shut down the sub-industry of cannabis extracts, affecting the use of CBD and other non-psychoactive cannabinoids in herbal remedies, cosmetics, and dietary supplements.
Some lawmakers and other experts have stated that the amendment would result in the closure of 3,000 businesses and the unemployment of 15,000 workers.
Finney stated that Cia-Agricoltori Italiani has invited government representatives to discuss with CBD operators.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
